Guidance on how to understand and overcome the barriers to engagement associated with rare diseases (for example, how a limited population can affect research, avoiding survey fatigue and maximising patient retention in clinical trials).

Strategic and practical support through the NICE evaluation process for rare disease treatments, including health economic models, submission dossiers and approaches to increase the chance of a successful outcome.

Relationships with rare condition opinion leaders and international patient groups, plus advice on how to plan and deliver advisory boards or focus groups on any topic.

Help to engage with rare disease individuals, groups and communites to gather data and insight. Support for connecting and communicating with NICE, NHS England and other public health bodies.